Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
5–13
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children and adolescents, 5 to 13 years of age
Diagnosis of fragile X syndrome based on prior DNA testing confirming Fragile X Mental Retardation 1 (FMR1) full mutation and qualifying scores on the ABC and CGI-S
You may not be if
Previous treatment with another mGlu5 receptor antagonist within the prior 3 months
Participation in a clinical trial involving an investigational drug (unapproved) or non-drug treatment within the prior 6 weeks or 5 times the half-life (whichever is longer) before the start of this study
Any uncontrolled, unstable clinically significant psychiatric condition other than fragile X syndrome
History of suicidal behavior
Clareo Health | A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
